Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -13.63
- Piotroski Score 2.00
- Grade Buy
- Symbol (EFTR)
- Company eFFECTOR Therapeutics, Inc.
- Price $0.00
- Changes Percentage (0%)
- Change -$0
- Day Low $0.00
- Day High $0.00
- Year High $17.90
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/20/2024
- Fiscal Year End N/A
- Average Stock Price Target $5.50
- High Stock Price Target $10.00
- Low Stock Price Target $1.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$12.57
- Trailing P/E Ratio -0.1
- Forward P/E Ratio -0.1
- P/E Growth -0.1
- Net Income $-35,811,000
